Monopar Therapeutics
Business
Monopar Therapeutics is a clinical-stage biopharmaceutical company developing ALXN1840, a late-stage oral investigational medicine for Wilson disease, and MNPR-101, a proprietary humanized monoclonal antibody platform for radiopharmaceutical imaging and therapy of uPAR-expressing advanced cancers. The company builds its pipeline through in-house development and licensing of late preclinical- and clinical-stage therapeutics. Monopar operates without owned manufacturing facilities, relying on third-party contract manufacturers and external vendors for drug substance and product supply.
Summary from 10-K filed 2026-03-27
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Research and development | 10 | 13 | 6 | 8 | 6 | |
| General and administrative | 7 | 3 | 3 | 3 | 3 | |
| Total operating expenses | 17 | 16 | 9 | 11 | 9 | |
| Loss from operations | −17 | −16 | −9 | −11 | −9 | |
| Other income | 0 | 171,282 | 0 | — | — | |
| Interest income | 3 | 404,020 | 429,039 | — | — | |
| Net loss | −14 | −16 | −8 | −11 | −9 | |
| Foreign currency translation (loss) gain, net | −4,189 | 1,630 | −17,272 | −2,937 | 4,713 | |
| Unrealized gain on investments, net | 99,586 | 48,494 | −5,802 | 15,039 | — | |
| Comprehensive loss | −14 | −16 | −8 | −11 | −9 | |
| Basic and diluted (in dollars per share) | −1.85 | −4.11 | −3.04 | −0.83 | — | |
| Basic and diluted** (in shares) | 7 | 4 | 3 | 13 | 12 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 62 | 46 | 7 | 8 | 20 | |
| Investments | 79 | 14 | 0 | 5 | 0 | |
| Other current assets | 63,745 | 78,869 | 66,433 | 45,982 | 217,745 | |
| Total current assets | 140 | 60 | 7 | 13 | 21 | |
| Operating lease right-of-use asset | 254,921 | 0 | 12,646 | 61,228 | 0 | |
| Total assets | 141 | 60 | 7 | 13 | 21 | |
| Accounts payable, accrued expenses and other current liabilities | 3 | 2 | 2 | 3 | 2 | |
| In-process R and D accrued expenses | 0 | 3 | 0 | — | — | |
| Total current liabilities | 3 | 5 | 2 | 3 | 2 | |
| Operating lease liability - non-current | 154,920 | 0 | 0 | 8,408 | 0 | |
| Total liabilities | 3 | 5 | 2 | 3 | 2 | |
| Commitments and contingencies (Note 9) | — | — | — | — | — | |
| Common stock, par value of $0.001 per share, 40,000,000 shares authorized, 6,692,140 and 6,102,560 shares issued and outstanding at December 31, 2025, and December 31, 2024, respectively** | 6,692 | 6,103 | 2,981 | 12,947 | 12,598 | |
| Additional paid-in capital | 227 | 131 | 66 | 62 | — | |
| Accumulated other comprehensive income | 131,389 | 35,992 | −14,132 | 8,942 | −3,160 | |
| Accumulated deficit | −90 | −76 | −60 | −52 | −41 | |
| Total stockholders equity | 138 | 55 | 6 | 10 | 19 | |
| Total liabilities and stockholders equity | 141 | 60 | 7 | 13 | 21 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Stock-based compensation expense | 5 | 1 | 2 | 2 | — | |
| Issuance of common stock to Alexion Pharmaceuticals, Inc | 0 | 5 | 0 | — | — | |
| Net amortization of investment discounts and premiums | −716,464 | −9,016 | — | — | — | |
| Other current assets | 15,404 | −12,776 | −20,410 | 171,755 | −86,198 | |
| Accounts payable, accrued expenses and other current liabilities | 388,218 | 506,791 | −1 | 1 | — | |
| In-process R&D accrued expenses | −3 | 3 | 0 | — | — | |
| Operating lease right-of-use assets and liabilities, net | −9,432 | 4,238 | 0 | −4,238 | — | |
| Net cash used in operating activities | −12 | −6 | −8 | −7 | −7 | |
| Purchase of short-term investments | −87 | −15 | −8 | −5 | — | |
| Maturities of short-term investments | 24 | 985,730 | 13 | 0 | — | |
| Net cash used in investing activities | −63 | −14 | 5 | −5 | 0 | |
| Cash proceeds from the sales of common stock under a Capital on DemandTM Sales Agreement, net of commissions, fees and expenses | 0 | 4 | 2 | 109,337 | — | |
| Taxes paid related to net share settlement of vested restricted stock units | −1 | −104,220 | −46,969 | −76,633 | — | |
| Cash proceeds from the issuance of common stock upon exercise of stock options | 565,171 | 84 | 0 | 169 | 17,478 | |
| Net proceeds from issuance of common stock and concurrent issuance of pre-funded warrants upon public offering, net of offering costs | 127 | 55 | — | — | — | |
| Repurchase of common stock | −35 | 0 | — | — | — | |
| Net cash provided by financing activities | 92 | 59 | 2 | 32,873 | 11 | |
| Net increase in cash and cash equivalents | 16 | 39 | −920,114 | −12 | 4 | |
| Effect of exchange rate and valuation changes on cash equivalents | 97,266 | 494 | −16,796 | −3,478 | — | |
| Lease liability arising out of obtaining right-of-use asset | 291,429 | 0 | — | — | — | |
| Accrued financing fees | 0 | 144,588 | — | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Monopar Therapeutics's CIK number?
Monopar Therapeutics's SEC CIK number is 0001645469 (1645469). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Monopar Therapeutics's SEC filings?
All of Monopar Therapeutics's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Monopar Therapeutics last report earnings?
Monopar Therapeutics (MNPR) most recently filed an earnings 8-K with the SEC on May 14, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001437749-26-016981). This is Monopar Therapeutics's most recent earnings filing of record — not a forecast of its next earnings date.
What is Monopar Therapeutics's most recent earnings 8-K?
Monopar Therapeutics's latest earnings 8-K (Item 2.02) was filed May 14, 2026 under accession 0001437749-26-016981. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Monopar Therapeutics's latest earnings 8-K →
Look up any company's CIK number →